Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2018 FY- Text added to 2019 FY
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
Abraxane, Addendum, Apexigen, azacytidine, Brazil, BRCA, breakthrough, Breast, brentuximab, Bristol, cabiralizumab, cascade, CFR, counterparty, CP, Crazy, CTA, cutoff, daratumumab, Daurismo, DCR, debilitating, devimistat, discomfort, downturn, dyspnea, effectuating, ELLO, Ellomay, eryaspase, Erytech, ESMO, exact, extinguishment, fast, Fifteen, fluorouracil, FOLFIRI, FOLFIRINOX, fundraising, gemcitabine, gemtuzumab, GI, glasdegib, grossly, ground, hard, hindsight, ibrutinib, IDH, IFRIC, immunosuppressive, implicit, incidental, InMode, IO, Irinotecan, ivosidenib, LV, Lynparza, Macroglobulemia, mavorixafor, metastasized, Mexico, motixafortide, motor, Mylotarg, nineteen, nominee, nonclinical, Nonproprietary, ODA, Otsuka, outbreak, pandemic, payroll, portal, PR, radiologic, redemption, redirecting, remeasurement, Rydapt, SD, Seattle, SITC, sooner, stockbroker, surrogate, Tibsovo, transform, unadjusted, unobservable, unrecognized, uprolesan, Vanflyta, vehicle, Waldenstrom, whichever, WHIM, wholly, widespread, workday, Xospata
Removed:
abbreviated, Abridged, absorbed, acknowledgement, Aladdin, alginate, Ambit, AMI, ANDA, Arabia, arbitration, Article, autoimmune, BCM, Bellerophon, beta, bibliographic, Bioabsorbable, bioavailability, bioequivalence, bioequivalent, biosimilar, biotechnological, block, bortezomib, BPCIA, BPD, Budget, cannabinoid, Cardiac, catalyst, choice, Chugai, cited, CMD, coherence, consistency, constituent, convened, coupled, CTI, declaratory, deliver, destroyed, disagreement, discontinued, disorder, diversity, documentation, dossier, draft, Eli, encourage, engineered, epidemiological, erlotinib, essentially, ethnic, excellent, expiry, explained, exploited, eye, Fabre, founder, gene, honeymoon, Hong, IDE, incorporate, infarction, infringed, innovator, insulin, Interbank, interchangeable, interventional, Janssen, JHL, justified, Kong, labelling, leaflet, Liechtenstein, Lilly, literature, MAA, Matrix, Mekinist, microbiological, module, myocardial, nancial, NASH, Negev, novo, objection, Odomzo, Opdivo, orally, OrbiMed, originator, owing, pacritinib, pharmaceutically, pharmacological, Pierre, PMA, polymer, possessing, postmarket, potency, predefined, presently, PRESERVATION, principle, procedural, progressively, protein, Qinprezo, rationale, raw, recombinant, RedHill, remodeling, renamed, resorbable, revision, Saudi, SE, secrete, sense, Singapore, smaller, SmPC, sodium, somatic, sonidegib, South, spending, stating, strength, substitution, Switzerland, systematic, Taiwan, Takeda, Tarceva, trametinib, transparent, Turkey, unique, updated, uprosertib, utilizing, Velcade, ventricular, viral, vorinostat, vosaroxin, yield, young, Zolinza
Valuein 2018 FY filing- Value in 2019 FY filing
Original filings
Filing view